Tuesday, January 19, 2016 9:13:57 AM
[Rockwell Medical Announces Two Triferic® Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 ? May 1, 2016 in Boston, MA
Ticker Symbol: U:RMTI
WIXOM, Mich., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that two Triferic abstracts have been selected by the National Kidney Foundation (NKF) for presentation at their Spring Clinical Meetings to be held April 27 ? May 1, 2016 at the Hynes Convention Center, Boston, MA. Triferic is the Company’s iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
The following abstracts have been accepted to be printed in the American Journal of Kidney Disease and for poster presentation at the NKF meetings:
Triferic Maintains Hemoglobin and Iron Balance Long Term: Open-Label Phase III Extension Studies
Pharmacology of Triferic in Chronic HD Patients
About Triferic
Triferic is a unique iron replacement product that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron loss that occurs during their dialysis treatment. Triferic is added to the bicarbonate concentrate on-site at the dialysis clinic. Once in dialysate, Triferic crosses the dialyzer membrane and enters the blood where it immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Triferic delivers sufficient iron to the bone marrow and maintains hemoglobin without increasing iron stores (ferritin). Please visit www.triferic.com or call Rockwell Medical at 800-449-3353 for more information.
About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.
Rockwell’s Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin without increasing iron stores (ferritin).
Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.
Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities.
Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information./b]
Recent RMTI News
- Rockwell Medical Named a Fortune 'Best Workplaces in Manufacturing & Production' • Business Wire • 09/18/2024 08:30:00 PM
- Rockwell Medical Named a Fortune 'Best Workplaces in Manufacturing & Production' • Business Wire • 09/18/2024 10:00:00 AM
- Rockwell Medical Announces Product Purchase Agreement with Leading At-Home and Acute Care Dialysis Provider • Business Wire • 09/09/2024 10:00:00 AM
- Rockwell Medical Enters into Multi-Million Dollar Distribution Agreement with Nipro Medical Corporation • Business Wire • 09/03/2024 10:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/20/2024 06:22:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:51:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:00:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 10:14:18 AM
- Rockwell Medical Reports Profitability on a Cash Flow and Adjusted EBITDA Basis in the Second Quarter of 2024 • Business Wire • 08/08/2024 10:00:00 AM
- Rockwell Medical Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities • Business Wire • 08/07/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 10:50:39 AM
- Rockwell Medical to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference • Business Wire • 07/15/2024 10:45:00 AM
- Rockwell Medical to Release Second Quarter 2024 Results on Thursday, August 8, 2024 • Business Wire • 07/11/2024 10:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 11:51:54 PM
- Rockwell Medical Promotes Tim Chole to Chief Commercial Officer • Business Wire • 05/30/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:10:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:07:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:06:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:02:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:12:01 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM